Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00020332
First received: July 11, 2001
Last updated: June 14, 2013
Last verified: July 2002
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have locally advanced or metastatic breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: alvocidib
Drug: docetaxel
Phase 1
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: October 2000
Study Completion Date: March 2003
Detailed Description:

OBJECTIVES:

  • Determine the maximum tolerated dose of docetaxel and flavopiridol in patients with previously treated locally advanced or metastatic breast cancer.
  • Determine the dose-limiting toxicity, toxicity profile, and pharmacokinetics of this regimen in these patients.
  • Determine the activity of this regimen in these patients.
  • Determine the objective response rate in patients treated with this regimen.
  • Determine immune dysfunction produced by this regimen as measured by lymphocyte subpopulations, including T-cell activation/memory subsets and natural killer cell/lymphokine-activated killer cell functional subsets in these patients.
  • Determine the ability of positron emission tomography scanning to predict response in patients treated with this regimen.
  • Determine the response duration, time to treatment failure, and overall survival of patients treated with this regimen.
  • Determine the quality of life of patients treated with this regimen.
  • Determine whether this regimen is associated with the development of a prothrombotic state in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive docetaxel IV over 1 hour on day 1 followed by flavopiridol IV over 1 hour or IV continuously on days 2-4. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

Sequential dose escalation of docetaxel is preceded or followed by sequential dose escalation of flavopiridol. Cohorts of 3-6 patients receive escalating doses of docetaxel preceded or followed by escalating doses of flavopiridol until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 22 additional patients are accrued to receive flavopiridol and docetaxel at the recommended phase II dose.

Quality of life is assessed at baseline, every 3 courses during study, and then at completion of study.

PROJECTED ACCRUAL: A total of 49 patients (27 for phase I and 22 for phase II) will be accrued for this study within 2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed stage III or IV adenocarcinoma of the breast
  • Phase I:

    • Evaluable disease allowed
  • Phase II:

    • At least 1 site of measurable disease
  • No bone metastasis as only site of disease
  • No carcinomatous meningitis or brain metastases
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Sex:

  • Male or female

Menopausal status:

  • Not specified

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • No active coagulopathy requiring therapeutic anticoagulation

Hepatic:

  • Bilirubin no greater than upper limit of normal (ULN)
  • SGOT no greater than 1.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN
  • No Gilbert's disease

Renal:

  • Creatinine no greater than 1.5 mg/dL

Cardiovascular:

  • Left ventricular ejection fraction at least 50% without clinical signs or symptoms of heart failure
  • No uncontrolled hypertension (sustained systolic blood pressure (BP) greater than 180 mm Hg or diastolic BP greater than 100 mm Hg)
  • No uncontrolled cardiac arrhythmia
  • No myocardial infarction within the past year
  • No significant ischemia or valvular heart disease

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No medical or psychiatric condition that would increase risk
  • No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanomatous skin cancer
  • No grade 2 or greater peripheral neuropathy
  • No diabetes mellitus with a fasting blood sugar greater than 200 mg/dL
  • No active unresolved infection
  • No serious concurrent medical illness
  • No history of hypersensitivity reaction to products containing polysorbate 80 (Tween 80)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior flavopiridol
  • Prior adjuvant chemotherapy for advanced disease allowed if within 6 months of diagnosis of metastatic disease
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or 8 weeks for UCN-01) and recovered
  • Phase I:

    • Any number of prior chemotherapy regimens for metastatic carcinoma of the breast allowed
  • Phase II:

    • No more than 2 prior chemotherapy regimens for metastatic carcinoma of the breast

Endocrine therapy:

  • Prior hormonal therapy in the metastatic or adjuvant setting allowed
  • At least 2 weeks since prior hormonal therapy and no evidence of disease improvement by radiography after therapy
  • Concurrent corticosteroids allowed if for study premedication or hypersensitivity reactions/adverse events

Radiotherapy:

  • No concurrent radiotherapy

Surgery:

  • Not specified

Other:

  • No other concurrent antineoplastic therapies
  • No other concurrent investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00020332

Locations
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
Investigators
Study Chair: Antoinette R. Tan, MD National Cancer Institute (NCI)
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00020332     History of Changes
Obsolete Identifiers: NCT00006277
Other Study ID Numbers: CDR0000068292, NCI-00-C-0212, NCI-952
Study First Received: July 11, 2001
Last Updated: June 14, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV breast cancer
stage IIIA breast cancer
recurrent breast cancer
stage IIIB breast cancer
male breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Alvocidib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Growth Inhibitors
Growth Substances
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 28, 2014